Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

 | Feb 05, 2020 09:24PM ET

Becton, Dickinson and Company (NYSE:BDX) , also known as BD, reported first-quarter fiscal 2020 earnings per share (EPS) of $2.65, which beat the Zacks Consensus Estimate of $2.63. The bottom line however dropped 1.9% on a year-over-year basis and fell 0.4% at constant currency (cc).

The Zacks Rank #4 (Sell) company raked in revenues of $4.23 billion, surpassing the Zacks Consensus Estimate of $4.17 billion. The reported figure improved 1.6% from the year-ago quarter. At cc, revenues rose 2.5%.

Segment Details

BD Medical

In the quarter under review, the company reported worldwide revenues of $2.09 billion, down 2.1% from the year-ago quarter and 1.1% at cc. Per management, the segment's results were offset by year-over-year declines in the Medication Management Solutions and Diabetes Care units.

BD Life Science

Worldwide revenues in the segment totaled $1.12 billion, up 6.3% year over year and 6.4% at cc. Per management, the upside was driven by solid performance in the Diagnostic Systems and Biosciences units.

BD Interventional

This segment generated worldwide revenues of $1.01 billion, up 4.3% from the year-ago quarter. At cc, revenues grew 5% on strong performance by the Surgery, Urology and Critical Care and Surgery sub-units.

Becton, Dickinson and Company Price, Consensus and EPS Surprise

.

Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, beating the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).

Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny, comparing favorably with the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.

IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes